Structural Insights into Biased Signaling at Chemokine Receptor CCR7

This study elucidates the structural basis of biased agonism at the chemokine receptor CCR7 by revealing how distinct binding modes of ligands CCL19 and CCL21 differentially modulate intracellular receptor dynamics to either permit or preclude kinase engagement, thereby driving divergent signaling outcomes.

The Gist

Imagine your immune system is a highly organized city, and CCR7 is the main traffic control tower at the city gates. Its job is to direct immune cells (like police officers) to where they are needed most.

This tower receives two different types of radio messages from the city: CCL19 and CCL21. Even though both messages say "Go to the gate," they tell the tower to do two very different things:

• CCL19 is like an urgent, short-range siren. It tells the tower to wake up the police, get them moving fast, and then immediately call them back to rest. It's a "burst" of activity.
• CCL21 is like a steady, long-distance GPS signal. It tells the tower to keep the police moving steadily for a long time without stopping, guiding them across the whole city to a distant location.

Scientists have long wondered: How does the same traffic tower (CCR7) react so differently to these two similar messages?

This paper uses high-tech "microscopes" (Cryo-EM) and computer simulations to take a 3D look inside the tower while it's listening to these messages. Here is what they found, explained simply:

1. The Two Keys Fit the Same Lock, But Differently

Think of CCR7 as a complex lock. CCL19 and CCL21 are two different keys.

• Both keys fit into the main keyhole (the receptor's core).
• However, the shape of the key's handle is different.
  • CCL21 has a small, compact handle that dives deep into the lock mechanism, wedging itself in tight.
  • CCL19 has a bulkier handle that sits more on top of the lock, resting lightly.

Because the handles sit differently, they twist the internal gears of the lock in slightly different ways.

2. The "Swinging Door" (The Helix 8)

The most important discovery is about a specific part of the lock called Helix 8. Imagine this as a swinging door on the inside of the tower that controls who gets let in next.

• When CCL21 (the GPS) is in the lock: The door gets stuck shut. It locks into a rigid position. This is perfect for keeping the "police" (G-proteins) engaged for a long time, but it prevents the "resting crew" (arrestins) from coming in to turn off the signal. This explains why CCL21 creates long, sustained movement.
• When CCL19 (the Siren) is in the lock: The door becomes wobbly and flexible. It swings open and closed, creating a gap. This gap allows a different team (GRKs and arrestins) to step in, turn off the signal, and pull the tower down for a break. This explains why CCL19 creates a short, intense burst of activity followed by a shutdown.

3. The "Dynamic Selection" Theory

The scientists realized that the bias isn't just about the shape of the lock; it's about the dancing.

• CCL21 forces the lock to stand perfectly still and rigid.
• CCL19 allows the lock to dance and wiggle.

This "wiggle" is crucial because it opens a side door that the "turn-off crew" needs to enter. If the lock is too stiff (like with CCL21), that side door stays closed, and the signal keeps going.

4. Why This Matters

Understanding this mechanism is like finding the blueprint for a master key.

• If we can design drugs that mimic the CCL21 style (stiff, long-lasting), we could create vaccines that help immune cells travel long distances to fight cancer or infections more effectively.
• If we can design drugs that mimic the CCL19 style (wobbly, short-burst), we could create treatments that quickly calm down an overactive immune system (like in autoimmune diseases) and then turn it off to prevent side effects.

In a nutshell: The same receptor can do two different jobs not because it changes its shape entirely, but because different ligands (keys) make it dance in different ways. One dance keeps the party going; the other dance invites the bouncer to shut it down early. This paper shows us exactly how the dance moves work.

Technical Summary

1. Problem Statement

The CC chemokine receptor 7 (CCR7) is a critical G protein-coupled receptor (GPCR) that orchestrates adaptive immunity by guiding immune cell migration to secondary lymphoid organs. It is activated by two endogenous ligands, CCL19 and CCL21, which exhibit biased agonism:

• CCL19: Induces robust G protein signaling and strong $\beta$-arrestin recruitment, leading to rapid receptor desensitization and internalization (transient signaling).
• CCL21: Preferentially activates G protein pathways with minimal $\beta$-arrestin engagement, resulting in sustained signaling and long-range chemotaxis.

Despite the physiological importance of this divergence, the structural and dynamic mechanisms underlying how these two ligands, which share a conserved core, elicit such distinct signaling outcomes at the same receptor have remained elusive. Previous structural data were limited to inactive states or small-molecule antagonists, leaving the active-state conformational landscape undefined.

2. Methodology

The study employed an integrated approach combining high-resolution structural biology, computational simulations, and functional assays:

• Cryo-Electron Microscopy (Cryo-EM):
  • Sample Preparation: The authors engineered a stable, active-state CCR7-Gi complex using a temporally controlled expression system in Expi293Fi cells. They utilized a NanoBiT system (LgBiT on CCR7, HiBiT on G$\beta$) for non-covalent tethering and a dominant-negative G$\alpha$i fusion for stability. The complex was further stabilized by the fiducial marker scFv16.
  • Data Collection: High-resolution maps were obtained for CCR7 bound to CCL19 (3.0 Å) and CCL21 (3.2 Å) in complex with the heterotrimeric Gi protein.
• Molecular Dynamics (MD) Simulations:
  • Six independent all-atom MD simulations (2.3 $\mu$s each) were performed for both CCL19- and CCL21-bound CCR7 complexes after removing the G protein and scFv16. This allowed the observation of receptor dynamics in a lipid bilayer environment relevant to downstream signaling events (e.g., GRK recruitment).
• Functional Assays:
  • NanoBiT-based assays: Used to measure G protein dissociation (Gi1) and $\beta$-arrestin2 membrane recruitment in HEK293T cells.
  • Site-Directed Mutagenesis: Structure-guided mutations (Y83A, R88A, D94A, D336A) were introduced to validate the functional relevance of specific structural features identified in the simulations.
  • Flow Cytometry: Used to confirm that mutations did not affect cell surface expression levels.

3. Key Contributions and Results

A. Distinct Ligand Binding Modes (Extracellular)

While both ligands bind to the same orthosteric pocket, they adopt markedly different orientations:

• CCL21: Its compact 30s loop (residues 28–37) inserts deeply into the receptor's extracellular vestibule, wedging between the chemokine N-terminus and the receptor's Extracellular Loop 2 (ECL2). This deep insertion stabilizes a specific ECL2 conformation.
• CCL19: Its corresponding 30s loop is bulkier and rests atop ECL2 rather than penetrating the pocket.
• Consequence: This difference in the Chemokine Recognition Site 3 (CRS3) interface drives a global rotation of the chemokine core (~17.6°) and alters the conformation of the extracellular ends of transmembrane helices (TM1, TM3, TM5, TM7).

B. Unique Activation Mechanism (TM6 Movement)

CCR7 activation differs from the canonical "hinge-like" pivot seen in many Class A GPCRs (e.g., CCR2, CXCR2):

• Mechanism: Instead of a pivot, CCR7 undergoes a parallel outward shift of the entire Transmembrane Helix 6 (TM6) by 3–4 Å.
• Structural Basis: This is attributed to the substitution of the conserved W6.48 (tryptophan toggle switch) with Q6.48 (glutamine) in CCR7. The smaller glutamine allows the extracellular end of TM6 to pack closer to TM3 in the inactive state, requiring a rigid-body lateral shift rather than a microswitch-driven pivot upon activation.

C. Intracellular Dynamics and Biased Signaling (The "Dynamic Selection" Model)

Despite similar Gi-coupled conformations in the static cryo-EM structures, MD simulations revealed critical differences in receptor dynamics after G protein dissociation:

• Helix 8 (H8) Dynamics:
  • CCL19-bound: The receptor exhibits high flexibility. The TM7-H8 loop dynamically inserts inward toward the receptor core (narrowing the TM2-TM7 gap), creating a lateral opening. This "open" state is stabilized by a salt-bridge network involving R88 (ICL1), D94 (TM2), and D336 (H8).
  • CCL21-bound: The receptor is "locked" in a conformation resembling the Gi-bound state. The H8 remains stable, and the critical R88-D94 salt bridge is largely absent, preventing the inward shift of H8.
• The Y83 Microswitch: The distinct binding modes propagate an allosteric signal to the intracellular end of TM1, altering the rotameric state of Y83 (1.57). This change dictates the conformation of ICL1 and the subsequent H8 dynamics.

D. Functional Validation

Mutagenesis confirmed the structural model:

• Y83A Mutation: Shifted signaling preference toward $\beta$-arrestin, suggesting Y83 is critical for the conformational transition required for Gi coupling.
• R88A and D94A Mutations: These disrupted the dynamic network required for the "open" H8 state. Both mutants showed reduced $\beta$-arrestin recruitment (loss of the open state) but retained robust Gi signaling (locked in the Gi-favorable state).
• Conclusion: CCL19's ability to sample the "open" H8 state facilitates GRK/$\beta$-arrestin engagement, while CCL21's "locked" state precludes this, explaining the G protein bias.

4. Significance

• Mechanistic Insight: This study resolves the long-standing paradox of how CCL19 and CCL21 induce biased signaling at CCR7. It demonstrates that bias is not solely determined by the initial G protein-bound state but by the post-G-protein conformational ensemble and the receptor's dynamic flexibility.
• General GPCR Principles: It highlights a "dynamic selection" model where ligand-specific dynamics (specifically H8 flexibility) determine effector selectivity (G protein vs. GRK/$\beta$-arrestin). This parallels findings in other receptors like the $\mu$-opioid receptor but reveals a unique mechanism involving H8 insertion rather than TM7 inward shift.
• Therapeutic Implications: The findings provide a structural blueprint for the rational design of pathway-selective immunomodulators. Drugs mimicking the CCL21 binding mode could act as G protein-biased agonists to promote sustained immune cell trafficking (e.g., for vaccines or cancer immunotherapy), while those mimicking CCL19 could induce transient activation for acute immune tuning.
• Structural Biology: It establishes the first high-resolution active-state structures of a chemokine receptor with its native protein ligands, revealing a non-canonical activation mechanism (rigid-body TM6 shift) specific to the CCR7 subfamily.